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The phosphatidylinositol 3-kinase (PI3K) pathway plays a pivotal role in the maintenance of processes such as cell growth, pro-
liferation, survival, and metabolism in all cells and tissues. Dysregulation of the PI3K/Akt signaling pathway occurs in patients
with many cancers and other disorders. This aberrant activation of PI3K/Akt pathway is primarily caused by loss of function of
allnegative controllers knownas inositolpolyphosphatephosphatasesandphosphoproteinphosphatases.Recent studies provided
evidence of distinct functions of the four main phosphatases—phosphatase and tensin homologue deleted on chromosome 10
(PTEN), Src homology 2-containing inositol 5 -phosphatase (SHIP), inositol polyphosphate 4-phosphatase type II (INPP4B),
and protein phosphatase 2A (PP2A)—in diﬀerent tissues with respect to regulation of cancer development. We will review
the structures and functions of PTEN, SHIP, INPP4B, and PP2A phosphatases in suppressing cancer progression and their
deregulation in cancer and highlight recent advances in our understanding of the PI3K/Akt signalingaxis.
1.Introduction
The phosphatidylinositol (PI) 3-kinase (PI3K) signaling
pathway is a normal signal transduction cascade that exists
in all types of cells and is physiologically involved in cell pro-
liferation, survival, protein synthesis, metabolism, diﬀerenti-
ation, and motility. In physiological situations, many growth
factors and regulators can stimulate or activate this pathway.
The PI3K pathway contains the upstream PI3K, which phos-
phorylates the D-3 position of PI, PI 4-phosphate, and PI
4,5-bisphosphate (PIP2) to produce PI 3-phosphate, PI 3,4-
bisphosphate (PI(3,4)P2), and PI 3,4,5-trisphosphate (PI(3,
4,5)P3orPIP3),respectively [1],as well as Aktand itskinases
PDK1, targets at Thr308 of Akt, and PDK2 which targets at
Ser473 of Akt [2]. The second messengers of PIs are associ-
ated with major cellular functions such as growth, diﬀeren-
tiation, apoptosis, protein traﬃcking, and motility. Several
studies have identiﬁed inositol polyphosphate phosphatases,
including three major PIP2/PIP3-degrading enzymes: (1)
phosphatase and tensin homologue deleted on chromosome
10 (PTEN), an ubiquitously expressed tumor suppressor
that converts PI(3,4,5)P3 to PI(4,5)P2 by dephosphorylating
the 3-position of PI(3,4,5)P3; (2) Src homology 2 (SH2)-
containing inositol 5 -phosphatase (SHIP), which dephos-
phorylates the 5-position PI(4,5)P3 to produce PI(4)P and
hydrolyzes PI(3,4,5)P3 to PI(3,4)P2 phosphatase [3]; (3) in-
ositolpolyphosphate4-phosphatasetypeII(INPP4B),which
hydrolyzes the 4-position phosphates of PI(3,4)P2 [4, 5]a n d
LKB1 [6] of the downstream tuberous sclerosis complex 2
(TSC2) [7, 8] and eukaryotic initiation factor 4E-(eIF4E)
[9–11]. Besides these three major lipid phosphatases, other
phosphatases inhibit the PI3K/Akt pathway, such as the
serine/threonine phosphoprotein phosphatase (PPP) family
member PP2A [12, 13]. The PPP family has seven members:
PP1, PP2A, PP2B (commonly known as calcineurin), PP4,
PP5, PP6, and PP7. PP1 and PP2 are the most abundant and
ubiquitous serine/threonine protein phosphatases in this
family. To date, PP2A is the only known Akt-Thr308 phos-
phatase [14, 15]. Unlike PP1 and PP2A, the in vitro basal
activity of PP4, PP5, PP6, and PP7 is extremely low. PP2C
(pleckstrin homology domain leucine-rich repeat protein
phosphatase) belongs to a novel PP2C-type phosphatase
family, the PPM subfamily. Pleckstrin homology do-
main leucine-rich repeat protein phosphatase functions as2 Enzyme Research
a “brake” for Akt and protein kinase C signaling, which has
beenextensively reviewed [16].Hereinwe describethe struc-
tures of PTEN, SHIP, INPP4B, and PP2A phosphatases. We
also characterize their functions in tumorigenesis and high-
l i g h to u rc u r r e n tk n o w l e d g eo ft h eP I 3 K / A k tp a t h w a y .
2.PTEN
2.1. PTEN Function: The Main Brake for TumorDevelopment.
PTEN/MMAC (mutated in multiple advanced cancers), that
controls negatively the PI3K/Akt pathway, is a tumor sup-
pressor gene. PTEN normally inhibits PI3K/AKT activation
by dephosphorylating PIP3 and PIP2, thus suppressing
tumor formation [3, 17–19]. Two groups initially and simul-
taneously identiﬁed PTEN/MMAC as a candidate tumor
suppressor gene located at 10q23 [20, 21]. Another group
found that the protein transforming growth factor-(TGF-)
β—regulated and epithelial cell-enriched phosphatase 1
encodedby the TEP1 gene is identical to the protein encoded
by the candidate tumor suppressor gene PTEN/MMAC1 in
a search for new dual-speciﬁcity phosphatases [22]. Loss of
heterozygosity of PTEN at chromosome 10q22–25 occurs in
multiple tumor types, most prominently advanced glial tu-
mors (glioblastoma multiforme and anaplastic astrocytoma)
but also prostate, endometrial, renal, and small cell lung
carcinoma; melanoma; meningioma. Germline mutations
in PTEN are present in cases of Cowden disease and Ban-
nayan-Zonana syndrome, two related hereditary cancer-
predisposition syndromes associated with elevated risk of
breast and thyroid cancer [23, 24]. Somatic mutations and
biallelic inactivation of PTEN are frequently observed in
high-grade glioblastomas, melanomas, and cancers of the
prostate and endometrium, among others [25].
Loss of PTEN function leads to increased concentrations
ofPIP3,themain in vivosubstrate ofPTEN,resulting in con-
stitutive activation of downstream components of the PI3K
pathway, including the kinases AKT and mammalian target
of rapamycin, mTOR [3]. One study found that 37 (36%) of
103 endometrial cancers exhibited PTEN-negative immuno-
histochemical staining and a signiﬁcant inverse correlation
between expression of PTEN and that of phosphorylated
AKT [26]. Another study has observed PTEN loss in both
late- and early-stage melanoma cases [27]. In addition, an
in vivo loss-of-function assay showed that Pten+/− mice ex-
perienced spontaneous development of tumors of various
histological origins [17, 18]. Moreover, PTEN inactivation
dramatically enhanced the ability of embryonic stem cells to
generate tumors in nude and syngeneic mice. An early study
found only 2% of PTEN mutations in hormone receptor-
positive breast cancers and identiﬁed about 20% of all PTEN
mutations in breast cancer cell lines [28]. This suggested
that PTEN mutation-associated cell lines are more viable in
culture than patient tumors. Recent studies have shown that
the frequencies of breast cancer cases associated with a loss
ofPTEN expression are, respectively, 30%inprimary tumors
and 25% in metastatic tumors [29], both higher values than
those reported earlier by Stemke-Hale et al. [28]. Thus,
regulation of PTEN expression at the posttranscriptional
level plays a more critical role in breast cancer development
compared to any genomic variations in PTEN. Besides
breast cancers, researchers have characterized about 38% of
patientswith nonsmall celllungcanceras havingPTEN dele-
tions/mutations [30]. Interestingly, Forgacs and colleagues
have reported a relatively low frequency (<10%) of somatic
intragenic PTEN mutations in small-cell lung cancers and
only two silent mutations and two apparent homozygous
deletions in 22 primary small-cell lung cancer tumors and
metastases [31]. Also, loss of heterozygosity of the PTEN/
MMAC1 locus has been found in all histologic types of
primary lung cancer [31]. More than 33% of PTEN allelic
deletions occurred before lung metastasis developed [32]. In
prostate cancer, the rates of PTEN loss ofheterozygosityhave
beenmuchhigher.Speciﬁcally,about56%ofprostatetumors
have heterozygous alterations in PTEN at presentation, and
about 90% of metastases have loss of the same allele [33].
In summary, PTEN performs diﬀerently in suppressing
cancer progression in various tissues because of inconsistent
occurrence of loss-of-function mutations.
3.INPP4B
INPP4B was initially isolated from rat brain and shown to
be an enzyme that primarily hydrolyzes the 4-position phos-
phate of PI(3,4)P2 into PI(3)P in vivo and slightly hydrolyzes
PI(3,4,5)P3 in vitro [34, 35].
3.1. INPP4B Structure. Although the INPP4Aα and
INPP4Bα isoforms have hydrophilic C-terminus regions, the
INPP4Aβ and INPP4Bβ isoforms have hydrophobic C-
termini that contain potential transmembrane domains. Ad-
ditionally, INPP4A and INPP4B share 37% amino acid iden-
tity. The murine Inpp4b locus was mapped on chromosome
8 in a synthetic synthesized region of the human 4q27–31
interval between Il-15 and Usp38. The murine INPP4B pro-
teins include the α and β isoforms encoded by this locus.
These two isoforms contain 927 and 941 amino acids, resp-
ectively, with consensus phosphatase catalytic sites and
conserved C2 domains that are highly similar to those of the
human and rat homologues. The C2 domain at the N-
terminus of INPP4B is the lipid-binding domain. The Nervy
homology 2 domain is the internal domain as well as a C-
terminal phosphatase domain. Human and murine INPP4B
C2 lipid-binding domains share greater than 91% sequence
identity [36] .T h em u r i n eI N P P 4 B - α and -β spliced isoforms
are highly conserved and have diﬀerent expression patterns
and cell localization [36].
3.2. INPP4B and Cancer. Increasing evidence has conﬁrmed
that INPP4B is a tumor suppressor gene. Westbrook and
colleagues identiﬁed INPP4B as a tumorigenesis-restraining
gene in a nonbiased RNAinterference-based screen for genes
with functional relevance to tumor initiation and devel-
opment that suppress transformation of human mammary
epithelial cells [37]. INPP4B expression was silenced in ma-
lignantproerythroblasts;thesecellsdisplayedincreasedlevels
of phosphorylated Akt expression that could be reduced byEnzyme Research 3
reexpression of INPP4B [38]. The INPP4B locus is located
on chromosome 4q31.21, a region that is frequently deleted
in breast cancer cell lines and high-grade basal-like breast
tumors as determined using high-resolution comparative
genomic hybridization analysis [39–41]. These ﬁndings have
been further supported by subsequent studies. Loss of
heterozygosity of INPP4B is frequently observed in BRCA1-
mutant and hormone receptor-negative breast cancer cells.
Loss of INPP4B protein expression in breast and ovarian
cancer cells is associated with decreased patient survival
rates. In human mammary epithelial cells and breast cancer
cell lines, INPP4B was able to suppress both basal [5]a n d
insulin-like growth factor-induced Akt phosphorylation [4].
Further evidence of INPP4B as a tumor suppressor gene
comes from a nonbiased RNAi-based genetic screen. The
lossofINPP4Bpromotestheanchorage-independentgrowth
of human mammary epithelial cells [37]. In particular,
INPP4B protein expression is lost in 84% of human basal-
like breast carcinomas, which are generally highly aggressive
with poor clinical outcomes and frequently associated with
BRCA1 gene mutations [42]. Authors have reported that
INPP4B is expressed in nonproliferative estrogen receptor-
(ER-)positive normal breast cells and breast cancer cell lines
but not in ER-negative breast cancer cell lines [4]. Further-
more, INPP4B knockdown in ER-positive breast cancer cells
increased Akt activation, cell proliferation, and xenograft
tumor growth. Conversely, reexpression of INPP4B in ER-
negative, INPP4B−/− human breast cancer cells reduced Akt
activation and anchorage-independent growth [4]. In the
same study, INPP4B protein expression was frequently lost
in primary human breast carcinoma cells, associated with
high clinical grade and large tumorsand loss ofexpression of
hormone receptors, and lost most often in aggressive basal-
like breast carcinomas [4]. INPP4B protein expression was
also frequently lost in PTEN-null tumors [5]. Androgen-
ablation therapies in the treatment of advanced prostate
cancers are associated with increased Akt signaling [43].
Androgens, therefore, play an important role in control of
the proliferation of prostate epithelial cells, through the
downregulation of Akt signaling. Activated-Akt signaling
stimulates cellular proliferation, cell survival, cell cycle
progression, growth, migration, and angiogenesis [44]. The
expression of INPP4B, which dephosphorylates PI(3,4)P2
and inactivates Akt and inhibits cellular proliferation, was
substantially lower in primary prostate tumors than that
in normal prostate tissue [45, 46]. Levels of INPP4B are
found to be induced by the androgen receptor in prostate
cancer cells and play an important role in androgen-ablation
therapy of prostate cancers [45]. The INPP4B expression
levels should be taken in consideration when Androgen-
ablation therapies are utilized for patients with advanced
prostate cancers.
4.SHIP
The cDNA-encoding isoform of the 145-kD protein SHIP
(alsocalledSHIP1)wasinitiallyclonedfromamurine hema-
topoietic cell line and named B6SUtAI. B6SUtAI was then
identiﬁed as the novel SH2-containing inositol polyphos-
phate 5-phosphatase SHIP. SHIP speciﬁcally hydrolyzes PIP3
and inositol 1,3,4,5-tetraphosphate [47]. The same group
identiﬁedandclonedhuman SHIPandmappedittothelong
arm of chromosome 2 at the border between 2q36 and 2q37
[48].
4.1. SHIP1 Structure and Function. SHIP1 contains 1190
amino acids and several identiﬁable motifs important for
protein-protein interactions, including an N-terminal SH2
domain, a central 5 -phosphoinositol phosphatase domain,
two phosphotyrosine binding consensus sequences, and a
proline-rich region at the carboxyl tail. Human SHIP shares
87.2% sequence identity with mSHIP [48].
SHIP is expressed ubiquitously in diﬀerentiated cells in
the hematopoietic system [47, 49, 50], endothelial cells [51],
hematopoieticstemcells,and embryonic stemcells[52].Par-
ticularly, SHIP1 can be phosphorylated at the tyrosine of the
ﬁrst NPXY motif located in the N-terminal SH2 domain [53,
54] in response to activation of hematopoietic cell surface
receptors, such as erythropoietin, steel factor, interleukin-
3[ 55, 56], interleukin-2, granulocyte-macrophage colony-
stimulating factor, and macrophage colony-stimulating fac-
tor, by numerous cytokines[57]. In one study,the number of
granulocyte-macrophage progenitors in both the bone mar-
row and spleen increased in SHIP1-knockout mice [58, 59].
SHIP1 is essential for normal bone homeostasis, as absence
of SHIP1 results in severe osteoporosis [60]. SHIP1 also
reduces the proliferation of osteoclasts via Akt-dependent
alterations in D-type cyclins and p27 [61].
SHIP1is an antagonist of cell growthand proliferationin
the hematopoietic system. Investigators ﬁrst veriﬁed SHIP1
as a tumor suppressor in conditional B-cell PTEN/SHIP1
knockout mice. They established B-cell-speciﬁc deletion of
both Pten and Ship (bPTEN/SHIP−/−)b ym a t i n gb P T E N −/−
mice with a novel strain of mice lacking SHIP only in B cells
(bSHIP−/−). The mice lacking expression ofPTEN and SHIP
in B cells develop lethal B-cell lymphomas with similarities
to human mature B-cell lymphomas. Loss of both PTEN and
SHIP expression in B cells results in an aggressive, often fatal
B-cell lymphoma disease. All B-cell PTEN/SHIP1-knockout
mice died by 1 year of age [62], thus, suggesting that SHIP1
and PTEN coordinately suppress B lymphoma development.
4.2. SHIP2 Structure and Function. The SHIP isozyme
SHIP2, also named INPPL1, is a 155-kD phosphatase that
is more widely expressed than is SHIP1 [63]. The SHIP2
cDNA was initially cloned from skeletal muscle, and the
lipid phosphatase that hydrolyzes the 5 -phosphate of the
inositol ring from in PIP3 was identiﬁed. SHIP2 is more
broadly detected than SHIP1, which is mainly expressed in
hematopoietic cells [64]. Human SHIP2 is highly expressed
in adult heart, skeletal muscle,and placenta. SHIP2 regulates
insulin signaling, and geneticSHIP2 knockoutprevents diet-
induced obesity in mice [65]. SHIP2also regulates cytoskele-
ton remodeling and receptor endocytosis. In another study,
SHIP2 expression was elevated in 44% of clinical breast
tumor specimens [66]. Furthermore, SHIP2 is a positive4 Enzyme Research
regulator of the epidermal growth factor receptor/Akt path-
way, C-X-C chemokine receptor type 4 expression, and cell
migration in MDA-MB-231 breast cancer cells [67].
Despite the potential microRNAs (miRNAs) to regulate
approximately one third of the entire genome, relatively few
miRNA targets SHIP2 have been validated experimentally,
particularly in stratiﬁed squamous epithelia. Yu and col-
leagues showed that miRNA-205 suppresses the expression
of lipid phosphatase SHIP2 in epithelial cells [68]. They
found that SHIP2 levels correlate reciprocally with elevated
miRNA-205 levels in aggressive squamous cell carcinoma
(SCC) cells. Downregulation of miRNA-205 expression in
squamous cell carcinoma cells leads to decreased phos-
phorylated Akt and phosphorylated Bcl-2—associated death
promoter expression and increased apoptosis [68]. The
function of miRNA-205 in SHIP2 expression is negatively
regulated by miRNA-184 in keratinocytes. Downregulation
of miRNA-205 expression by ectopic expression of miRNA-
184 increases SHIP2 expression and impairs the ability of
keratinocytes wound healing. Keratinocytes not only express
theepidermalgrowthfactor(EGF)receptorbutalso produce
ligandsforthisreceptor,includingTGF-α,amphiregulin,and
HB-EGF.EGFandTGF-αpromotekeratinocyteproliferation
and migration [69]. Many cellular processes, such as altered
cell adhesion, expression of matrix-degrading proteinases,
and cell migration, are common to keratinocytes during
wound healing and in metastatic tumors. Yu and colleagues
provided abundant evidence that SHIP2 is involved in
keratinocyte migration promoted by miRNA-205 [70].
5.PP2A
PP2A is a major serine/threonine protein phosphatase in
mammalian cells. It accounts for up to 1% of all cellular
proteins and, together with PP1, accounts for 90% of all ser-
ine/threonine phosphatase activity in most tissues and cells
[71]. PP2A is highly conserved from yeast to humans, and its
regulatory mechanism is extraordinarily complex.
5.1. PP2A Structure and Function. Several holoenzyme com-
plexes of PP2A have been isolated from a variety of tissues
and extensively characterized. The core enzyme of PP2A is a
dimer (PP2AD) consisting of a 65-kD scaﬀolding A subunit
(also termed PR65/A and PP2R) and a 36-kD catalytic C
or A subunit. The scaﬀolding Aα subunit of PP2A contains
15 Huntington, elongation factor 3, a subunit of PP2A, and
target of rapamycin 1 repeats [72]. The third regulatory B
subunit of PP2A, which includes at least 18 regulatory
subunitsthathavebeenclassiﬁedB(B55orPR55),B  (B56or
PR61), B   (PR48/PR72/PR130), and B    (PR93/PR110), is
associated with the core enzyme. Studies identiﬁed a unique
C-terminal tail (residues 294–309) in PP2A’s C subunit,
which contains a motif (TPDY307FL309) that is highly
conserved and exists in the catalytic subunits of all PP2A-
like phosphatases, including PP4 and PP6. Methylation of
Leu309 in this C-terminal tail can promote recruitment of
the regulatory B/B /B   subunits to the A/C dimer [73]. The
Huntington, elongation factor 3, a subunit of PP2A, and
target of rapamycin 1 repeats in the scaﬀold A subunit
play roles in holding the catalytic C and regulatory B  sub-
units together. To date, researchers have identiﬁed ﬁve pri-
mary members of the B56 family (α, β, γ, δ,a n dε)
that are encoded by diﬀerent genes—PPP2R5A, PPP2R5B,
PPP2R5C, PPP2R5D, and PPP2R5E—which are mapped to
the loci 1q41, 11q12, 3p21, 6p21.1, and 7p11.2, respectively
[74]. B56 subunits of PP2A share a highly conserved central
region of 80% identity (which comprises two A-subunit
bindingdomains). These regulatory B subunitsplaykeyroles
incontrollingPP2Asubstratespeciﬁcity,cellularlocalization,
and enzymatic activity [75]. These regulatory subunits are
expressed in speciﬁc tissues and lead to the formation of
diﬀerent PP2A complexes mammalian tissues [76]. In com-
parison, three subunits of B56 family—B56β,B 5 6 δ,a n d
B56ε—exist primarily in the brain, whereas two others—
B56alpha and B56gamma—are highly expressed in cardiac
and skeletal tissue [74]. PP2A expression is regulated by
both C-terminal methylation and phosphorylation of the C
subunit residue Tyr307; tyrosine kinases such as Src inhibit
PP2A activity [77], and phosphorylation of the B56 subunit
by Erk inhibits PP2A assembly [78].
T h ea c t i v ec o r ed i m e ro fP P 2 Ai n t e r a c t sw i t haw i d ev a r i -
ety of regulatory subunits (B subunits) and generates more
than 60 diﬀerent heterotrimeric PP2A holoenzymes that
dictate the functions of individual forms. These regulatory
subunits typically increase the formation of stable complexes
of PP2A with its substrates. PP2A has the remarkable ability
to interact with structurally distinct regulatory subunits and
form complexes with many diﬀerent substrates owing to the
inherent ﬂexibility of the scaﬀold subunit A, which is com-
posed of 15 tandem HEAT repeats. These 60 holoenzymes
catalyze distinct dephosphorylation events that result in spe-
ciﬁc functional outcomes [79]. PP2A complexes have been
implicated in regulation of the mitogen-activated protein
kinase, Wnt, PI3K, nuclear factor-κB, protein kinase C, and
Ca2+/calmodulin-dependent signaling pathways as well as
downstream targets of these and other pathways. In most
pathways, the speciﬁc constituents of the regulatory PP2A
complexes have yet to be determined. PP2A dephosphory-
lates multiple components of these signaling pathways in
vitro, and increasing in vivo evidence supports the physio-
logical relevance of many of these interactions [80].
5.2. PP2A and Cancer. The role of the tumor suppressor
PP2A in controlling tumor progression is thought to be gov-
erned by a small subset of speciﬁc B subunits directing PP2A
to dephosphorylate and regulate key tumor suppressors or
oncogenes[76, 81].Indeed, severalmembers oftheB56fam-
ily have been described as having a role in directing PP2A’s
tumor-suppressive activity. PP2A was initially identiﬁed as
a tumor suppressor in studies in which okadaic acid was
found to be a potent carcinoma inducer in a mouse model
(Figure 1)[ 82]. Okadaic acid was also found to be selective
inhibitor of PP2A activity in these studies. Ito and colleagues
observed that N-terminally truncated B56γ leads to en-
hanced invasiveness and neoplastic progression, transform-
ing melanoma cells from a nonmetastatic to a metastaticEnzyme Research 5
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Figure 1: The primary phosphatases function as tumor suppressors and their signaling pathways. This model demonstrates the roles of
PTEN, INPP4B, SHIP1/2, and PP2A in regulation of signaling downstream of PI3K/Akt. Two major phospholipid pools—PI(3,4,5)P3
and PI(3,4)P2—were generated in response to stimulation of PI3K. PTEN hydrolyzed the 3 -phosphate of PI(3,4,5)P3 to terminate PI3K
signaling. SHIP family members hydrolyzed the 5 -phosphate of PI(3,4,5)P3 to generate PI(3,4)P2, which, like PI(3,4,5)P3, can facilitate
PDK1-dependent phosphorylation and activation of AKT. INPP4B converted PI(3,4)P2 to PI(3)P. PP2A not only dephosphorylated Akt at
T308 and S473 and negatively regulated the PI3K/Akt pathway but also stabilized p53 or CDC25 and the 14-3-3 complex, inactivated the
oncoprotein c-Myc, and antagonized the Wnt/β-catenin pathway. Red arrows indicate enhancing tumorigenesis activities, and green arrows
indicate inhibition of tumorigenesis.
state[83].FurtherevidencesupportingPP2Aasatumorsup-
pressor comes from the ﬁnding that the small-t antigen (ST)
in two transforming DNA viruses, SV40 and polyoma virus,
causes cell transformation by binding to regulatory subunits
A and C of PP2A and displacing a single PP2A regulatory
subunit (B56γ) from PP2A complexes. This interaction is
essential for ST to transform cells [84, 85]. Another study
conﬁrmed PP2A to be the target of the adenoviral protein
E4orf4. It further suggested that PP2A, like other targets
of viral oncoproteins, plays an important role in tumor
suppression [86]. Mechanistically, downregulation of PP2A
expression by ST stabilizes the phosphorylation of proteins
such as c-Myc at Ser62 and p53 at either Thr55 or Ser37 and
causes cells to undergo uncontrolled growth [87–89]. Chen
and colleagues found that speciﬁc suppression of the B56γ
subunit replaced ST of SV40 or polyoma virus and induced
cell anchorage-independent growth and tumor formation
[87]. The B /B56/PR61γ subunit of PP2A is involved in tu-
mor formation. In addition, partial knockdown of ex-
pression of the PP2Aα subunit results in selective loss of
PP2A heterotrimers containing the B56γ subunit, and loss
of B56γ from PP2A complexes substitutes for the small
tumor antigen during transformation, as well. The partial
suppression of endogenous Aα leads to activation of Akt
kinase, suggesting that activation of the PI3K/Akt pathway
contributes to transformation. In addition, PP2A is involved
in cell transformation as an important tumor suppressor
[79]. Loss-of-function screening on PP2A by short hairpin
RNA recognized that PP2A Cα involved in the SV40 small
T-antigen caused human cell transformation but not Cβ
subunits or the PP2A regulatory subunits B56α,B 5 6 δ,a n d
PR72/PR130. Further evidence of PP2A as tumor suppressor
comes from the ﬁnding that inhibition of PP2A expression
by short hairpin RNA activates the PI3K/Akt and c-Myc
signaling pathways [90].
AlthoughmutationsofPP2AAαoccuratlowfrequencies
in human tumors, mutations of the second PP2A A subunit,
Aβ, are more common. Speciﬁcally, researchers found
somatic alterations, including point mutations, deletions,
frameshifts, and splicing abnormalities, of the PPP2R1B
gene, which encodes the PR65/A scaﬀold protein, in 15% of
primary lung tumors, 6% of lung tumor-derived cell lines,
13% of breast tumors, and 15% of primary colon tumors.
Missense mutations and homozygous deletions of the same
gene were found in 8% of patients and 2% of patients,
respectively, with colorectal cancer [91–94]. These cancer-
associated PP2A Aβ mutants are defective in binding to B
and/or C subunits in vitro [95]. In addition to mutations
of it, the PP2A Aβ gene is located at 11q23, a chromosomal
region frequently deletedin cancercells [96]. Also, PPP2R1A6 Enzyme Research
encoding the α-isoform of the scaﬀolding subunit of the
serine/threonine PP2A holoenzyme was recently found to
be mutated in 7% (3/42) of patients with ovarian clear cell
carcinoma [97]. Somatic missense mutations of PPP2R1A
have been demonstrated in 41% (20/49) of high-grade
serous endometrial tumors and 5% (3/60) of endometrial
endometrioid carcinomas. Another study identiﬁed muta-
tions of PPP2R1A in ovarian tumors but at lower frequen-
cies: 12% of endometrioid carcinomas and 4% of clear cell
carcinomas [98]. Very recently, the PPP2R5E gene, which
encodes a regulatory subunit of PP2A, was identiﬁed as
harboring genetic variants that aﬀect soft tissue sarcoma
[99].
5.3. PP2A as a Tumor Suppressor. Researchers found that
PPP2R1A and PPP2R5E mutations interfered with the bind-
ing of speciﬁc third regulatory B subunits of PP2A [95]. For
example, Damuni’s group identiﬁed SET as one of the heat-
stable PP2A protein inhibitors that induce leukemogenesis.
SET, also called template-activating factor 1β or phosphatase
2 Ai n h i b i t o r2 ,i san u c l e a rp h o s p h o p r o t e i n .S E Tw a sﬁ r s t
identiﬁed in a patient with acute nonlymphocytic myeloid
leukemia [100]. The SET gene is fused to CAN [101]. SET
expression is high in rapidly dividing cells but low in
quiescent and contact-inhibited cells. SET contributes to
tumorigenesis in part by forming an inhibitory protein com-
plex with PP2A [100]. Amino acid residues aﬀected by these
mutations are highly conserved across species and interact
directly with regulatory B subunits of the PP2A holoenzyme.
Additionally, investigators found the B56γ mutation F395C,
which is located in the B56γ-p53 binding domain, in lung
cancer cells. This mutation impairs the functions of B56γ-
PP2A in dephosphorylation of p53 at Thr55 [102].
Furthermore, B56ε (encoded by PPP2R5E), a B56-fam-
ily-regulatory subunit of PP2A, can trigger p53-dependent
apoptosis. Mechanistically, B56ε regulates the p53-depend-
ent apoptotic pathway solely by controlling the stability of
the p53 protein [103].
PP2A reportedly antagonizesthe Wnt/β-catenin pathway
via physical interaction of B56 subunits with Wnt pathway
components. In addition, treatment of HEK 293 cells with
okadaic acid, an inhibitor of PP2A, results in elevated β-
catenin protein expression [104]. Overexpression of PP2A:
B56ε inhibits Wnt/β-catenin signaling in tissue culture and
Xenopus embryos [104–106]. Loss-of-function analysis of
PP2A:B56εduringearlyXenopusembryogenesisshowedthat
PP2A: B56ε is required for Wnt/β-catenin signaling [107].
The B /B56/PR61 subunit binds to the tumor suppressor
adenomatous polyposis coli, which is a component of the
Wnt pathway. The Wnt pathway plays essential roles dur-
ing embryonic development and tumorigenesis [108, 109].
B56α-PP2A can dephosphorylate c-Myc at Ser62 and inac-
tivate the oncoproteinc-Myc [110, 111]. The protein cancer-
ous inhibitor of PP2A interacts directly with the oncogenic
transcription factor c-Myc by inhibiting the catalytic activity
of the PP2A holoenzyme toward c-Myc at Ser62, thereby
preventing c-Myc proteolytic degradation without aﬀecting
PP2A binding potential [112].
P P 2 Ai si n v o l v e di nr e g u l a t i o no fD N A - r e s p o n s i v eG 2 / M
checkpoints, as well. DNA-responsive checkpoints acti-
vate PP2A/B56δ phosphatase complexes to dephosphorylate
CDC25 at sites diﬀerent from Ser287 (Thr138), phospho-
rylation of which is required for release of 14-3-3 pro-
tein from CDC25. Ser287 phosphorylation is a major locus
ofG2/Mcheckpointcontrol.B56δ C-PP2ApromotesThr138
dephosphorylationandprevents14-3-3release.Thisrestricts
PP1 recruitment, CDC25 activation, and entry of cells from
G2 to M phase. Remarkably, the CHK1 kinase activated
during the replication checkpoint phosphorylates B56δ,e n -
hancing itsincorporation into PP2Aholoenzyme. Therefore,
B56δ-PP2A dephosphorylates Cdc25, blocking cell-cycle
progression as a central checkpointeﬀector[113, 114]. How-
ever, whether PP2A/B56δ phosphatase complexes are in-
volved in DNA repair must be clariﬁed.
In other experiments, researchers identiﬁed B56-con-
taining PP2As to be phosphatases of Akt and found that
PP2A reverses immediate early response gene X-1–mediated
Akt activation [115]. Immediate early response gene X-1,
also known as IER3, DIF2,a n dGly96, is an ubiquitous early
response gene product involved in cell proliferation and sur-
vival. The cell proliferation and survival is rapidly induced
in response to various growth factors, cytokines, chemical
carcinogens, and viral infections [116]. Vereshchagina and
colleagues found that the protein phosphatase PP2A-B  sub-
unit Widerborst acts as a subcellular compartment-speciﬁc
regulator ofPI3K/PTEN/Aktkinase signalling and negatively
regulates cytoplasmic Akt activity in Drosophila [117]. A
more recent study conﬁrmed that B56β (PPP2R5B, B β)
plays a critical role in the assembly of the PP2A holoenzyme
complex on Akt, which leads to dephosphorylation of both
Ser473 and Thr308 Akt sites. However, Cdc2-like kinase 2
phosphorylates the PP2A regulatory subunit B56 β and trig-
gers the assembly procession of PP2A holoenzyme complex
and subsequently downregulates Akt activity [118]. More-
over, a study identiﬁed PP2A (encoded by PPP2R5E) along
with BIM (Bcl2L11), an AMP-activated kinase (encoded by
Prkaa1), and the tumorsuppressor phosphatase PTEN as the
targetsofmiRNA-19inNotch-inducedacuteT-cell leukemia
cells [119].
In general, the genetic and epigenetic changes in PP2A
complexes in human cancer cells remain to be deﬁned, as
does their impact on cancer signaling and therapeutic re-
sponses to targeted therapy. One of the PP2A-regulated can-
cersignaling pathwaysisthemammalian targetofrapamycin
pathway, a key component of the PI3K pathway that many
cancer cells are “addicted” for growth.
6.Conclusion
SHIP1/2, PP2A, INPP4B, and PTEN are commonly viewed
as opposingthe activity ofthePI3K/Aktsignaling axis, which
promotessurvivalofcancercellsandtumors.Itiscertainthat
the enzymatic activities of 3  polyphosphatase work as nega-
tive controller. Most powerfully, PTEN downregulatesPI3K’s
reaction by converting PI(3,4,5)P3 to PI(4,5)P2.W h e r e a st h e
5  polyphosphatase activity of SHIP1/2 converts PI(3,4,5)P3Enzyme Research 7
to PI(3,4)P2. This distinction is potentially crucial, as it may
enable SHIP1/2 and PTEN to have distinctly diﬀerent eﬀects
on Akt signaling. PTEN expression is a relatively ubiquitous
negative regulator of the PI3K/Akt signaling pathway. Loss-
of-function PTEN mutation/deletions lead to the develop-
ment of all types of cancer. SHIP1 is speciﬁcally expressed in
all cells of the hematopoietic system and is correlated with
T- and B-cell lymphoma development. SHIP2 functions as
a positive regulator of the epidermal growth factor receptor/
Akt pathway, C-X-C chemokine receptor type 4 expression,
and cell migration in breast cancer cells but a negative
regulator of keratinocyte migration. INPP4B speciﬁcally
hydrolyzes PI(3,4)P2 to be PI(3)P, negatively regulates the
PI3K/Akt pathway, and has emerged as a potential tumor
suppressor in prostate, breast, and ovarian cancers and, pos-
sibly, leukaemias. PP2A, as a tumor suppressor, is more
complicated than other phosphatases because it has ﬁve
regulatory subunits that exist in diﬀerent tissues and play
diﬀerent roles in various cells. These ﬁve subunits are in-
clined to be mutated and aﬀect their own function. Most
of the mutations of these ﬁve subunits remain unidentiﬁed.
How PTEN, SHIP1/2, INPP4B, and PP2A orchestrate to
sustain normal signaling and achieve eﬃcient inhibition of
the PI3K/Akt pathway in all types of cells and tissues is still
far from being completely determined.
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